Company Nymox Pharmaceutical Corporation
Equities
NYMXF
BSP733981026
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3 USD | 0.00% | +3.38% | -49.15% |
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Patrick Doody
BRD | Director/Board Member | - | 11/07/23 |
Director/Board Member | - | 20/03/23 | |
Suresh Kalbag
PRN | Corporate Officer/Principal | - | - |
General Counsel | - | 05/02/20 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David S. Morse
BRD | Director/Board Member | 67 | 07/06/06 |
Paul Averback
CEO | Chief Executive Officer | 73 | 29/05/95 |
Director/Board Member | 88 | 30/06/15 | |
Director/Board Member | - | 20/03/23 | |
Patrick Doody
BRD | Director/Board Member | - | 11/07/23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 93,265,000 | 54,049,529 ( 57.95 %) | 0 | 57.95 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-49.15% | 28.01M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- NYMXF Stock
- Company Nymox Pharmaceutical Corporation